Logo image of ENGN

ENGENE HOLDINGS INC (ENGN) Stock Fundamental Analysis

NASDAQ:ENGN - CA29286M1059 - Common Stock

4.8 USD
+0.18 (+3.9%)
Last: 9/2/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, ENGN scores 2 out of 10 in our fundamental rating. ENGN was compared to 542 industry peers in the Biotechnology industry. The financial health of ENGN is average, but there are quite some concerns on its profitability. ENGN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year ENGN has reported negative net income.
ENGN had a negative operating cash flow in the past year.
In the past 5 years ENGN reported 4 times negative net income.
In the past 5 years ENGN always reported negative operating cash flow.
ENGN Yearly Net Income VS EBIT VS OCF VS FCFENGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

With a decent Return On Assets value of -29.96%, ENGN is doing good in the industry, outperforming 66.97% of the companies in the same industry.
ENGN's Return On Equity of -35.14% is fine compared to the rest of the industry. ENGN outperforms 74.54% of its industry peers.
Industry RankSector Rank
ROA -29.96%
ROE -35.14%
ROIC N/A
ROA(3y)-5.96%
ROA(5y)N/A
ROE(3y)-6.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENGN Yearly ROA, ROE, ROICENGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

ENGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENGN Yearly Profit, Operating, Gross MarginsENGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

5

2. Health

2.1 Basic Checks

The number of shares outstanding for ENGN has been increased compared to 1 year ago.
Compared to 1 year ago, ENGN has a worse debt to assets ratio.
ENGN Yearly Shares OutstandingENGN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M 50M
ENGN Yearly Total Debt VS Total AssetsENGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ENGN has an Altman-Z score of 1.85. This is not the best score and indicates that ENGN is in the grey zone with still only limited risk for bankruptcy at the moment.
ENGN has a Altman-Z score of 1.85. This is in the better half of the industry: ENGN outperforms 68.27% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that ENGN is not too dependend on debt financing.
ENGN has a worse Debt to Equity ratio (0.09) than 63.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 1.85
ROIC/WACCN/A
WACCN/A
ENGN Yearly LT Debt VS Equity VS FCFENGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 12.66 indicates that ENGN has no problem at all paying its short term obligations.
The Current ratio of ENGN (12.66) is better than 86.53% of its industry peers.
A Quick Ratio of 12.66 indicates that ENGN has no problem at all paying its short term obligations.
ENGN's Quick ratio of 12.66 is amongst the best of the industry. ENGN outperforms 86.53% of its industry peers.
Industry RankSector Rank
Current Ratio 12.66
Quick Ratio 12.66
ENGN Yearly Current Assets VS Current LiabilitesENGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

1

3. Growth

3.1 Past

ENGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -56.01%.
EPS 1Y (TTM)-56.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ENGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.63% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-40.66%
EPS Next 2Y-26.34%
EPS Next 3Y-7.72%
EPS Next 5Y18.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENGN Yearly Revenue VS EstimatesENGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ENGN Yearly EPS VS EstimatesENGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENGN. In the last year negative earnings were reported.
Also next year ENGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENGN Price Earnings VS Forward Price EarningsENGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENGN Per share dataENGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as ENGN's earnings are expected to decrease with -7.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.34%
EPS Next 3Y-7.72%

0

5. Dividend

5.1 Amount

No dividends for ENGN!.
Industry RankSector Rank
Dividend Yield N/A

ENGENE HOLDINGS INC

NASDAQ:ENGN (9/2/2025, 8:00:01 PM)

4.8

+0.18 (+3.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-12 2025-06-12/bmo
Earnings (Next)09-11 2025-09-11
Inst OwnersN/A
Inst Owner Change-1.25%
Ins OwnersN/A
Ins Owner Change0%
Market Cap245.33M
Analysts84.71
Price Target21.98 (357.92%)
Short Float %N/A
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.57%
Min EPS beat(2)-26.76%
Max EPS beat(2)-0.38%
EPS beat(4)2
Avg EPS beat(4)0.23%
Min EPS beat(4)-26.76%
Max EPS beat(4)16.34%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-2.31
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0
BVpS4.45
TBVpS4.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.96%
ROE -35.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-5.96%
ROA(5y)N/A
ROE(3y)-6.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.66
Quick Ratio 12.66
Altman-Z 1.85
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.46%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.21%
EPS Next Y-40.66%
EPS Next 2Y-26.34%
EPS Next 3Y-7.72%
EPS Next 5Y18.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-152.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-81.18%
EBIT Next 3Y-35.73%
EBIT Next 5Y14.43%
FCF growth 1Y-8069.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8006.67%
OCF growth 3YN/A
OCF growth 5YN/A